Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies.
Leclercq G, Haegel H, Schneider A, Giusti AM, Marrer-Berger E, Boetsch C, Walz AC, Pulko V, Sam J, Challier J, Ferlini C, Odermatt A, Umaña P, Bacac M, Klein C. Leclercq G, et al. Among authors: boetsch c. J Immunother Cancer. 2021 Jul;9(7):e002582. doi: 10.1136/jitc-2021-002582. J Immunother Cancer. 2021. PMID: 34326166 Free PMC article.
CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity.
Solomon I, Amann M, Goubier A, Arce Vargas F, Zervas D, Qing C, Henry JY, Ghorani E, Akarca AU, Marafioti T, Śledzińska A, Werner Sunderland M, Franz Demane D, Clancy JR, Georgiou A, Salimu J, Merchiers P, Brown MA, Flury R, Eckmann J, Murgia C, Sam J, Jacobsen B, Marrer-Berger E, Boetsch C, Belli S, Leibrock L, Benz J, Koll H, Sutmuller R, Peggs KS, Quezada SA. Solomon I, et al. Among authors: boetsch c. Nat Cancer. 2020 Dec;1(12):1153-1166. doi: 10.1038/s43018-020-00133-0. Epub 2020 Nov 9. Nat Cancer. 2020. PMID: 33644766 Free PMC article.
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors.
Peters S, Angevin E, Alonso-Gordoa T, Rohrberg K, Melero I, Mellado B, Perez-Gracia JL, Tabernero J, Adessi C, Boetsch C, Watson C, Dal Porto J, Dejardin D, Del Nagro C, Nicolini V, Evers S, Klein C, Leutgeb B, Pisa P, Rossmann E, Saro J, Umana P, Charo J, Teichgräber V, Steeghs N. Peters S, et al. Among authors: boetsch c. Clin Cancer Res. 2024 Apr 15;30(8):1630-1641. doi: 10.1158/1078-0432.CCR-23-2658. Clin Cancer Res. 2024. PMID: 38319672
Optimizing Early Clinical Investigations in Cancer Immunotherapy: The Translational Journey of RG6292, a Novel, Selective Treg-Depleting Antibody.
Belli S, Amann M, Hutchinson L, Pousse L, Abdolzade-Bavil A, Justies N, Jacobsen B, Ploix C, Tselempi E, Tosevski V, Koll H, Schnetzler G, Boetsch C, Marrer-Berger E. Belli S, et al. Among authors: boetsch c. Clin Pharmacol Ther. 2024 Sep;116(3):834-846. doi: 10.1002/cpt.3303. Epub 2024 May 20. Clin Pharmacol Ther. 2024. PMID: 38769868
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors.
Steeghs N, Gomez-Roca C, Rohrberg KS, Mau-Sørensen M, Robbrecht D, Tabernero J, Ahmed S, Rodríguez-Ruiz ME, Ardeshir C, Schmid D, Sleiman N, Watson C, Piper-Lepoutre H, Dejardin D, Evers S, Boetsch C, Charo J, Teichgräber V, Melero I. Steeghs N, et al. Among authors: boetsch c. Clin Cancer Res. 2024 Jul 1;30(13):2693-2701. doi: 10.1158/1078-0432.CCR-23-3567. Clin Cancer Res. 2024. PMID: 38630781 Free PMC article. Clinical Trial.
Industry Perspective on First-in-Human and Clinical Pharmacology Strategies to Support Clinical Development of T-Cell Engaging Bispecific Antibodies for Cancer Therapy.
Nagaraja Shastri P, Shah N, Lechmann M, Mody H, Retter MW, Zhu M, Li T, Wang J, Shaik N, Zheng X, Ovacik M, Hua F, Jawa V, Boetsch C, Cao Y, Burke J, Datta K, Gadkar K, Upreti V, Betts A. Nagaraja Shastri P, et al. Among authors: boetsch c. Clin Pharmacol Ther. 2025 Jan;117(1):34-55. doi: 10.1002/cpt.3439. Epub 2024 Sep 19. Clin Pharmacol Ther. 2025. PMID: 39295563 Review.
Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma.
Hansen AR, Gomez-Roca CA, Robbrecht DGJ, Verlingue L, Italiano A, Bauman JE, Steeghs N, Prenen H, Fayette J, Spicer J, Niu J, Habigt C, Schneider M, Evers S, Sleiman N, Dejardin D, Ardeshir C, Schmid D, Boetsch C, Charo J, Kraxner A, Teichgräber V, Keshelava N, Bonomi MR. Hansen AR, et al. Among authors: boetsch c. Clin Cancer Res. 2024 Dec 16;30(24):5540-5547. doi: 10.1158/1078-0432.CCR-24-1562. Clin Cancer Res. 2024. PMID: 39422604 Free PMC article. Clinical Trial.
First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors.
Hidalgo M, Martinez-Garcia M, Le Tourneau C, Massard C, Garralda E, Boni V, Taus A, Albanell J, Sablin MP, Alt M, Bahleda R, Varga A, Boetsch C, Franjkovic I, Heil F, Lahr A, Lechner K, Morel A, Nayak T, Rossomanno S, Smart K, Stubenrauch K, Krieter O. Hidalgo M, et al. Among authors: boetsch c. Clin Cancer Res. 2018 Apr 1;24(7):1536-1545. doi: 10.1158/1078-0432.CCR-17-1588. Epub 2017 Dec 7. Clin Cancer Res. 2018. PMID: 29217526 Clinical Trial.
25 results